Life Science Real Estate Vacancy Hits 24.3% as Sector Decouples from Record VC Funding

For decades, commercial real estate investors relied on a simple equation: when venture capital flows into biotechnology, demand for laboratory space follows. Today, that fundamental assumption is being shattered. In the second quarter of 2026, the life sciences sector recorded a massive influx of capital, with venture funding surging 52 percent year-over-year to reach $9.2 billion. Yet, despite this flood of investment, the real estate that houses these companies is experiencing its worst downturn in recent history. The tension between record-breaking biotech funding and empty physical laboratories has left market observers scrambling for answers. The resolution to this paradox lies in a combination of pandemic-era overbuilding and a quiet technological revolution that is permanently shrinking the industry's physical footprint.[1][4]

The disconnect is starkly visible in the latest market metrics. Across the top United States life sciences hubs, the overall vacancy rate has climbed to 24.3 percent, an increase of 195 basis points from the previous year. This rising emptiness has exerted severe downward pressure on pricing, with average asking rents falling 5.3 percent year-over-year to $64.17 per square foot. In major markets like Boston, San Diego, and the San Francisco Bay Area, the collective vacancy rate has reached an unprecedented 32 percent. The situation has forced major real estate investment trusts to report significant losses and offer unprecedented concessions just to maintain occupancy.[1][2][4][5]

To understand how the market reached this point, one must look back to the pandemic-era boom. Between 2020 and 2023, an explosion of interest in mRNA vaccines and therapeutics triggered a massive wave of speculative laboratory construction. Developers rushed to build millions of square feet of specialized research and development space, assuming that the rapid pace of biotech expansion would continue indefinitely. However, as macroeconomic conditions shifted and interest rates rose, tenant demand normalized while the newly constructed supply continued to deliver. The result was a historic supply-and-demand imbalance that the market is still struggling to digest.[2][4]

The sheer volume of the oversupply is staggering. Of the 60 million square feet of laboratory space completed between 2020 and 2025, more than half remains vacant. The situation is particularly acute for the newest vintage of buildings; properties completed in 2025 are facing vacancy rates exceeding 70 percent, with dozens of entire buildings sitting completely empty. This glut has transformed what was once a landlord-dominated sector into a fiercely competitive tenant's market. For a biotech startup looking for space today, the leverage is unprecedented—allowing them to demand move-in-ready suites and massive tenant improvement allowances that would have been unthinkable three years ago.[2][4]

Beyond the sheer oversupply, a fundamental technological shift is driving the decoupling of funding from real estate demand. The rapid advancement of artificial intelligence and machine learning has ushered in the era of "in silico" research—conducting biological experiments via computer simulation rather than in physical petri dishes. Biotech companies are increasingly utilizing AI for drug discovery and molecular modeling, which drastically reduces the need for traditional wet-lab space. As a result, life sciences firms are now taking roughly a third less physical space per employee than they did just a few years ago, fundamentally altering the industry's real estate footprint requirements.[2]

The second major factor reshaping the market is a pronounced "flight to quality." Because tenants now have an abundance of options, they are aggressively trading up to newer, state-of-the-art facilities that offer better amenities and more efficient infrastructure. Over the past nine months, buildings completed since the start of 2020 have successfully absorbed 2.6 million square feet of available space. Conversely, older laboratory properties built before 2000 have seen their available space increase by 700,000 square feet during the same period. This dynamic is creating a bifurcated market where premium assets slowly stabilize while older buildings face mounting obsolescence.[2]

As traditional biotech demand softens, landlords are increasingly looking to alternative tenant bases to fill their empty laboratories. A surprising new trend has emerged wherein artificial intelligence hardware firms, robotics manufacturers, and other "tough tech" companies are leasing specialized life science spaces. These companies require the heavy power infrastructure, reinforced flooring, and advanced HVAC systems that lab buildings provide. In Boston, for example, these alternative users now account for 30 percent of all laboratory leases signed in 2025, triple the share they represented just four years earlier.[2]

For an institutional owner managing a portfolio in Boston or San Diego, the prolonged slump is forcing difficult daily decisions. Alexandria Real Estate Equities, one of the largest life sciences landlords, recently posted a $73.7 million loss for the second quarter, accompanied by a 10 percent drop in net operating income. To secure tenants, landlords are being forced to offer massive concession packages, including extensive tenant improvement allowances and months of free rent. Average lease terms for direct relocations have also compressed significantly, dropping to 62 months—roughly 30 percent shorter than at the market's peak.[2][4]

Despite the grim vacancy numbers, there are early indicators that the market may be approaching a bottom. The most significant positive signal is the dramatic contraction of the construction pipeline. In the second quarter of 2026, no new life science properties were delivered across the 12 major markets tracked by Cushman & Wakefield—the first such quarter on record. This halt in new deliveries is allowing the market to begin absorbing the existing excess supply. Furthermore, of the 4.5 million square feet of new space expected to be delivered later in 2026, 72 percent is already preleased, indicating that the era of speculative overbuilding has effectively ended.[1][5]

While the bleeding may be slowing, the path to full recovery will be long and complex. Industry analysts project that the current supply-to-demand ratio sits near six-to-one, ensuring that rental rates will face continued downward pressure through the end of the decade. To reach equilibrium, a significant portion of the current inventory will need to be permanently removed from the life sciences pool. Projections indicate that nearly 19 million square feet of available laboratory space will likely need to be converted to alternative uses or demolished by 2030 due to distress and obsolescence.[2]

The current state of the life sciences real estate market serves as a powerful case study in how technological innovation can disrupt physical infrastructure needs. Just as remote work fundamentally altered the traditional office sector, the rise of computational biology is permanently reshaping the laboratory market. For investors and developers, the lesson is clear: capital inflows into an industry no longer guarantee a proportional increase in physical space requirements. Moving forward, the most successful real estate strategies will need to account for the increasing digitization of scientific research and the evolving nature of the modern laboratory.[6]

Ultimately, the life sciences sector is not in decline; rather, it is maturing and adapting to new realities. The robust venture capital funding and strong job growth in biotechnology research indicate that the underlying science remains highly valued by the market. However, the physical manifestation of that science has changed. As the industry continues to work through its historic supply glut, the real estate market that emerges on the other side will be leaner, more technologically integrated, and fundamentally decoupled from the simple square-footage metrics of the past.[3][6]